Advertisement

The 28-year-old rapper passed away in early August.

A coroner has confirmed Mac Miller’s cause of death. The 26-year-old rapper and music producer (born Malcolm McCormick) died at home in Studio City, California on Sept. 7. Given his history of substance use, early reports pointed to drugs.

On Monday (Nov. 7), the Los Angeles County Department of Medical Examiner-Coroner confirmed that McCormick had died from an accidental overdose of fentanyl, cocaine and alcohol due to mixed drug toxicity.

The rapper, who had a tour planned for October following the Aug. 3rd release of his album Swimming, was discovered by his personal assistant in his bedroom. McCormick “struggles with sobriety and when he ‘slips’ he consumes them in excess,” his assistant said, adding that he’d had “several recent ‘slips’” including one three days prior to his death.

In a 2015 interview with Billboard, the rapper said he was in a good place. “I’m not doing as many drugs. It just eats at your mind, doing drugs every single day, every second. It’s rough on your body,” he said.

Fentanyl, the synthetic opioid painkiller said to be 50 times stronger than heroin, has also been cited in the deaths of Prince (April 2016) and Tom Petty (October 2017). According to the National Center on Health Statistics, fentanyl was involved in 60% of opioid-related deaths in 2017, an 11% increase from five years prior.

While fentanyl was created for cancer pain, it is now fueling rising rates of drug overdose deaths. This has prompted the need for a stronger opioid overdose “antidote” to match the strength of increasingly potent fentanyl analogs.

And this month, the Food and Drug Administration approved a new, more powerful opioid painkiller called Dsuvia. This new drug is said to be 10 times stronger than fentanyl and 1,000 times stronger than morphine.

While Dsuvia is intended for restricted use only in health care settings—the FDA promised to place “very tight restrictions” on the drug—critics worry that it will only worsen the opioid crisis.

“We have worked very diligently over the last three or four years to try to improve the public health, to reduce the number of potent opioids on the street,” said Dr. Raeford Brown, who chairs the FDA advisory committee that voted to approve Dsuvia, despite his opposition. “I don’t think this is going to help us in any way.”

View the original article at thefix.com

Advertisement
Related Posts

Privacy Preference Center